Optimising cancer vaccine design in sarcoma

Alexandra Pender, Robin L. Jones, Seth Pollack*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Immunotherapeutics are increasingly recognized as a key tool in the armamentarium against malignancy. The success of immune checkpoint-targeting drugs and adoptive cell therapy has refocused attention on the potential anti-cancer effect of eliciting a tumour-specific immunological response. Sarcomas are a rare and diverse group of tumours with a limited prognosis in advanced disease despite systemic therapeutics. Various vaccine strategies including peptide vaccines against cancer testis antigens, dendritic cell vaccines, and viral vectors have been trialled in sarcoma with growing evidence of efficacy. Here, we review the principles of successful vaccine development and how these have been applied thus far to the treatment of sarcoma.

Original languageEnglish (US)
Article number1
Issue number1
StatePublished - Jan 1 2019
Externally publishedYes


  • Adjuvant
  • Antigen
  • Immune response
  • Peptide
  • Sarcoma
  • Vaccine
  • Virus

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Optimising cancer vaccine design in sarcoma'. Together they form a unique fingerprint.

Cite this